Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;155(9):861-868.
doi: 10.1001/jamasurg.2020.2423.

Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones

Calyani Ganesan  1 , Benjamin Weia  1 , I-Chun Thomas  2 , Shen Song  1 , Kyla Velaer  3 , Carolyn D Seib  4 , Simon Conti  3 , Chris Elliott  5 , Glenn M Chertow  1   6 , Manjula Kurella Tamura  1   2 , John T Leppert  1   2   3 , Alan C Pao  1   2   3
Affiliations

Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones

Calyani Ganesan et al. JAMA Surg. .

Abstract

Importance: Approximately 3% to 5% of patients with kidney stones have primary hyperparathyroidism (PHPT), a treatable cause of recurrent stones. However, the rate of screening for PHPT in patients with kidney stones remains unknown.

Objectives: To estimate the prevalence of parathyroid hormone (PTH) testing in veterans with kidney stones and hypercalcemia and to identify the demographic, geographic, and clinical characteristics of veterans who were more or less likely to receive PTH testing.

Design, setting, and participants: This cohort study obtained Veterans Health Administration (VHA) health records from the Corporate Data Warehouse for veterans who received care in 1 of the 130 VHA facilities across the United States from January 1, 2008, through December 31, 2013. Historical encounters, medical codes, and laboratory data were assessed. Included patients had diagnostic or procedural codes for kidney or ureteral stones, and excluded patients were those with a previous serum PTH level measurement. Data were collected from January 1, 2006, to December 31, 2014. Data analysis was conducted from June 1, 2019, to January 31, 2020.

Exposures: Elevated serum calcium concentration measurement between 6 months before and 6 months after kidney stone diagnosis.

Main outcomes and measures: Proportion of patients with a serum PTH level measurement and proportion of patients with biochemical evidence of PHPT who underwent parathyroidectomy.

Results: The final cohort comprised 7561 patients with kidney stones and hypercalcemia and a mean (SD) age of 64.3 (12.3) years. Of these patients, 7139 were men (94.4%) and 5673 were white individuals (75.0%). The proportion of patients who completed a serum PTH level measurement was 24.8% (1873 of 7561). Across the 130 VHA facilities included in the study, testing rates ranged from 4% to 57%. The factors associated with PTH testing included the magnitude of calcium concentration elevation (odds ratio [OR], 1.07 per 0.1 mg/dL >10.5 mg/dL; 95% CI, 1.05-1.08) and the number of elevated serum calcium concentration measurements (OR, 1.08 per measurement >10.5 mg/dL; 95% CI, 1.06-1.10) as well as visits to both a nephrologist and a urologist (OR, 6.57; 95% CI, 5.33-8.10) or an endocrinologist (OR, 4.93; 95% CI, 4.11-5.93). Of the 717 patients with biochemical evidence of PHPT, 189 (26.4%) underwent parathyroidectomy within 2 years of a stone diagnosis.

Conclusions and relevance: This cohort study found that only 1 in 4 patients with kidney stones and hypercalcemia were tested for PHPT in VHA facilities and that testing rates varied widely across these facilities. These findings suggest that raising clinician awareness to PHPT screening indications may improve evaluation for parathyroidectomy, increase the rates of detection and treatment of PHPT, and decrease recurrent kidney stone disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Cohort Diagram
PTH indicates parathyroid hormone.
Figure 2.
Figure 2.. Rate of Parathyroid Hormone (PTH) Testing in Patients With Kidney Stones and Hypercalcemia at Each Veterans Health Administration (VHA) Facility
Each bar indicates the SE of the PTH testing percent estimate for each VHA facility, and each diamond indicates the percent estimate for each facility.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rule AD, Lieske JC, Li X, Melton LJ III, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014;25(12):2878-2886. doi:10.1681/ASN.2013091011 - DOI - PMC - PubMed
    1. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989;111(12):1006-1009. doi:10.7326/0003-4819-111-12-1006 - DOI - PubMed
    1. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155(3):839-843. doi:10.1016/S0022-5347(01)66321-3 - DOI - PubMed
    1. Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project . Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165. doi:10.1016/j.eururo.2012.03.052 - DOI - PMC - PubMed
    1. Sharma S, Rastogi A, Bhadada SK, et al. . Prevalence and predictors of primary hyperparathyroidism among patients with urolithiasis. Endocr Pract. 2017;23(11):1311-1315. doi:10.4158/EP171759.OR - DOI - PubMed

Publication types

Substances